Kangpu Biopharmaceuticals is a clinical-stage company that specializes in the discovery and development of innovative small molecules aimed at treating a range of serious medical conditions, including autoimmune diseases, hematologic malignancies, solid tumors, and inflammatory disorders. The company leverages proprietary technology platforms such as NeoMIDES®, gDACs®, and X-SYNERGY® to create a robust pipeline of potential first-in-class and best-in-class drug candidates. A key focus of their research is on modulating the CRBN-E3 ubiquitin ligase complex (CRL4 CRBN), which plays a crucial role in the ubiquitin-proteasome system (UPS) responsible for regulating protein levels within cells. By altering substrate specificity within this pathway, Kangpu aims to target and degrade pathogenic proteins that contribute to various diseases.

One of the notable drug candidates in Kangpu's pipeline is KPG-818, a small molecule modulator of the CRBN E3 ubiquitin ligase complex. KPG-818 has shown promising preclinical results, demonstrating significant anti-inflammatory properties and anti-proliferative activities against multiple blood cancers. It effectively induces the ubiquitination and degradation of key transcription factors involved in B-cell development, such as Aiolos and Ikaros. Currently, KPG-818 is undergoing clinical trials for conditions like systemic lupus erythematosus (SLE) and hematological malignancies, with additional studies approved for its use in COVID-19 treatment. This innovative approach to drug development highlights Kangpu's commitment to addressing significant unmet medical needs through advanced therapeutic solutions.

China

Kangpu Biopharmaceuticals, Ltd. is a clinical-stage company focused on the discovery and development of innovative small molecules for the treatments of various diseases. The company has a robust pipeline of potential first-in-class and best-in-class drug candidates based on proprietary technology platforms.

Kangpu Biopharmaceuticals

Company Details